Literature DB >> 21479551

The chemokine receptor CCR4 promotes tumor growth and lung metastasis in breast cancer.

Ji-Yu Li1, Zhou-Luo Ou, San-Jian Yu, Xiao-Li Gu, Chen Yang, Ao-Xiang Chen, Gen-Hong Di, Zhen-Zhou Shen, Zhi-Ming Shao.   

Abstract

Increasing evidence has shown that chemokines and chemokine receptors are associated with tumor growth and metastasis. CCR4, an important chemokine receptor for regulating immune homeostasis, is thought to be involved in hematologic malignancies and has also recently implicated in some solid tumors, such as gastric cancer. The possible role of CCR4 in breast cancer has not been well elucidated. In this study, we show that CCR4 is differentially expressed in human breast cancer cell lines. Specifically, we find that CCR4 is overexpressed in breast cancer cell lines with high metastatic potential. More importantly, we used a combination of overexpression and RNA interference to demonstrate that CCR4 promotes breast tumor growth and lung metastasis in mice. Furthermore, we find that microvessel density is significantly increased in tumors formed by CCR4-overexpressing cells and decreased in those formed by CCR4-knockdown cells. We find that overexpression of CCR4 can enhance the chemotactic response of breast cancer cells to CCL17. However, the expression of CCR4 does not affect the proliferation of breast cancer cells in vitro. Furthermore, we show that CCR4 expression is positively correlated with HER2 expression, tumor recurrence and lymph node, lung and bone metastasis (P < 0.05). Multivariate analysis showed that CCR4 expression is a significant independent prognostic factor for overall survival (P = 0.036) but not for disease-free survival in patients with breast cancer (P = 0.071). Survival analysis indicated a strong association between CCR4 expression and lower overall survival (P = 0.0001) and disease-free survival (P = 0.016) in breast cancer.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21479551     DOI: 10.1007/s10549-011-1502-6

Source DB:  PubMed          Journal:  Breast Cancer Res Treat        ISSN: 0167-6806            Impact factor:   4.872


  44 in total

1.  Higher circulating levels of chemokine CCL22 in patients with breast cancer: evaluation of the influences of tumor stage and chemokine gene polymorphism.

Authors:  A Jafarzadeh; H Fooladseresht; K Minaee; M R Bazrafshani; A Khosravimashizi; M Nemati; M Mohammadizadeh; M M Mohammadi; A Ghaderi
Journal:  Tumour Biol       Date:  2014-10-22

Review 2.  Emerging targeted agents in metastatic breast cancer.

Authors:  Dimitrios Zardavas; José Baselga; Martine Piccart
Journal:  Nat Rev Clin Oncol       Date:  2013-03-05       Impact factor: 66.675

3.  Tumor-associated macrophage or chemokine ligand CCL17 positively regulates the tumorigenesis of hepatocellular carcinoma.

Authors:  Fangyu Zhu; Xiangnan Li; Siyu Chen; Qiu Zeng; Yu Zhao; Fang Luo
Journal:  Med Oncol       Date:  2016-01-19       Impact factor: 3.064

4.  A CCR4 antagonist reverses the tumor-promoting microenvironment of renal cancer.

Authors:  Chiara Berlato; Moddasar N Khan; Tiziana Schioppa; Richard Thompson; Eleni Maniati; Anne Montfort; Maryam Jangani; Monica Canosa; Hagen Kulbe; Urs B Hagemann; Alexander R Duncan; Laura Fletcher; Robert W Wilkinson; Thomas Powles; Sergio A Quezada; Frances R Balkwill
Journal:  J Clin Invest       Date:  2017-01-30       Impact factor: 14.808

5.  Expression of chemokine receptor 4 was associated with poor survival in renal cell carcinoma.

Authors:  Qiang Liu; Mulati Rexiati; Ying Yang; Wen-Guang Wang; Baihetiya Azhati; Weilijiang Saimaiti; Yu-Jie Wang
Journal:  Med Oncol       Date:  2014-02-20       Impact factor: 3.064

6.  TLR4 is a novel determinant of the response to paclitaxel in breast cancer.

Authors:  Sandeep Rajput; Lisa D Volk-Draper; Sophia Ran
Journal:  Mol Cancer Ther       Date:  2013-05-29       Impact factor: 6.261

7.  CCR4 mediates CCL17 (TARC)-induced migration of human colon cancer cells via RhoA/Rho-kinase signaling.

Authors:  Amr A Al-haidari; Ingvar Syk; Karin Jirström; Henrik Thorlacius
Journal:  Int J Colorectal Dis       Date:  2013-05-07       Impact factor: 2.571

8.  Cell surface receptor FPR2 promotes antitumor host defense by limiting M2 polarization of macrophages.

Authors:  Ying Liu; Keqiang Chen; Chunyan Wang; Wanghua Gong; Teizo Yoshimura; Mingyong Liu; Ji Ming Wang
Journal:  Cancer Res       Date:  2012-11-08       Impact factor: 12.701

9.  HIC1 deletion promotes breast cancer progression by activating tumor cell/fibroblast crosstalk.

Authors:  Yingying Wang; Xiaoling Weng; Luoyang Wang; Mingang Hao; Yue Li; Lidan Hou; Yu Liang; Tianqi Wu; Mengfei Yao; Guowen Lin; Yiwei Jiang; Guohui Fu; Zhaoyuan Hou; Xiangjun Meng; Jinsong Lu; Jianhua Wang
Journal:  J Clin Invest       Date:  2018-10-22       Impact factor: 14.808

10.  Complicated prognostic values of CCL28 in breast cancer by subtype.

Authors:  Di-He Gong; Yi-Yu Chen; Ding Ma; Hai-Yan Chen; Ke-Feng Ding; Ke-Da Yu
Journal:  J Thorac Dis       Date:  2019-03       Impact factor: 2.895

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.